Price
No data yet.
Social Signal Score
Analyst Ratings
9 analystsRevenue
$11.38M+6084.78%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Vishwas Seshadri
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 226
- Beta
- 1.32
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -3.04
Financials
Revenue
$11.38M+6084.8%Net Income
$-20.19MEBITDA
$-18.80MFree Cash Flow
$-17.98MEPS (diluted)
$-0.35Shares Outstanding (diluted)
57.05M+4186.1%Operating Expenses
$20.86MCash & Debt
$146.83MReturn of Capital
$0.00Revenue by Segment (annual)
$5.82MDividend per Share
$3706.25Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $5.82M | $71.18M | $1.34 |
| 2024 | $0.00 | $-63.73M | $-1.55 |
| 2023 | $3.50M | $-54.19M | $-2.53 |
| 2022 | $1.41M | $-39.70M | $-5.53 |
| 2021 | $3.00M | $-84.94M | $-21.50 |
| 2020 | $10.00M | $-84.23M | $-22.75 |
| 2019 | $0.00 | $-76.28M | $-38.07 |
| 2018 | $3.00M | $-56.67M | $-29.81 |
| 2017 | $837.0K | $-27.32M | $-16.40 |
| 2016 | $889.0K | $-21.87M | $-16.00 |
| 2015 | $1.04M | $-14.53M | $-13.16 |
| 2014 | $925.0K | $-26.78M | $-381.50 |
| 2013 | $2.04M | $4.45M | $76.75 |
| 2012 | $4.40M | $-10.53M | $-650.00 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $1.98
- Implied price
- $7.90
- Return from $5.03
- 9.5% a year
To earn 15.0% a year on these assumptions you'd need to buy at $3.93 — -21.9% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 0 | 2 | 4 | 6 | 8 |
|---|---|---|---|---|---|
| -2.0% | — | -13.5% | -0.7% | 7.7% | 14.1% |
| 3.0% | — | -9.1% | 4.4% | 13.2% | 19.9% |
| 8.0% | — | -4.7% | 9.5% | 18.7% | 25.7% |
| 13.0% | — | -0.3% | 14.5% | 24.2% | 31.5% |
| 18.0% | — | 4.1% | 19.6% | 29.7% | 37.4% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
113-26.63%Social Signal Score
Mentions (11)
- Newsmarketbeat.com·13d ago·Positive
Abeona Therapeutics Highlights ZEVASKYN Launch Momentum, Revenue Growth at H.C. Wainwright Abeona Therapeutics NASDAQ: ABEO highlighted the early commercial progress of ZEVASKYN, its autologous gene-modified cellular sheet therapy for recessive dystrophic epidermolysis bullosa (RDEB), during the H.C. Wainwright 28th Annual conference.
View source ↗ - Newsmarketbeat.com·14d ago·Neutral
Abeona Expands ZEVASKYN Network as RDEB Launch Gains Momentum Abeona Therapeutics NASDAQ: ABEO executives outlined the early commercial rollout of ZEVASKYN, an autologous cell sheet-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB), during the Morgan Stanley Global Healthcare Conference. Management emphasized that the launch requires a longer foundation-building period than a conventional drug because of the therapy's individualized manufacturing process, limited shelf lif…
View source ↗ - Newsbenzinga.com·18d ago·Negative
Abeona Stands to Collect Royalties After Ultragenyx's FDA Approval — Here's the Rest of the Week Abeona Therapeutics Inc. (NASDAQ:ABEO) had a busy week that included a new treatment center activation, an FDA approval for a drug the company licensed away and multiple fresh analyst ratings.
View source ↗ - Newsglobenewswire.com·18d ago·Neutral
Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA) - FDA approval represents a monumental milestone for patients with MPS IIIA and validates Abeona's foundational R&D and clinical development efforts -
View source ↗ - Newsseekingalpha.com·19d ago·Positive
Abeona Therapeutics Inc. (ABEO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Abeona Therapeutics Inc. (ABEO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·20d ago·Positive
…on of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN® CLEVELAND, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing genetic medicines for serious diseases with high unmet need, today announced the activation of University of Florida Health (UF Health) in Gainesville, Florida, as the eighth Qualified Treatment Center (QTC) for the administration of ZEVASKYN (prademagene zamikeracel) ge…
View source ↗ - Newsbusinesswire.com·27d ago·Negative
ABEO Investors Have Opportunity to Join Abeona Therapeutics Inc. Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $ABEO--ABEO Investors Have Opportunity to Join Abeona Therapeutics Inc. Fraud Investigation with SBS Law.
View source ↗ - Newsglobenewswire.com·34d ago·Neutral
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences CLEVELAND, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in September 2026:
View source ↗ - Newsseekingalpha.com·53d ago·Positive
Abeona Therapeutics Inc. (ABEO) Q2 2026 Earnings Call Transcript Abeona Therapeutics Inc. (ABEO) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·54d ago·Neutral
Abeona Therapeutics Q2 Earnings Call Highlights Abeona Therapeutics NASDAQ: ABEO reported second-quarter revenue growth from its ZEVASKYN cell therapy launch while outlining operational challenges involving patient scheduling and manufacturing that affected revenue recognition.
View source ↗ - Newsglobenewswire.com·54d ago·Negative
…6.8 million in cash, cash equivalents and short-term investments as of June 30, 2026 – CLEVELAND, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the second quarter of 2026 and provided an update on commercial execution for ZEVASKYN (prademagene zamikeracel). Commercial Update Steady launch-year growth for ZEVASKYN.
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-0.14 per share
Typical surprise +31.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.35 vs $-0.23miss
- Wed, May 13$-0.30 vs $-0.33beat
- Tue, Mar 17$-0.34 vs $-0.35beat
- Wed, Nov 12$-0.10 vs $-0.27beat
- Mon, Aug 11$1.71 vs $-0.39beat
- Wed, May 14$-0.24 vs $-0.35beat
Estimates and results for ABEO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ABEO officers and directors.
- Bought
- —
- Sold
- $5.7m
0 trades
62 trades
- Seshadri Vishwassold
- Vazzano Joseph Waltersold
- O'malley Brendan M.sold
- Vasanthavada Madhavsold
- Alvino Marksold
- Vazzano Joseph Waltersold
- Vazzano Joseph Waltersold
- Seshadri Vishwassold
38 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ABEO.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.